Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Agios Pharmaceuticals Inc (NASDAQ: AGIO) was $37.45 for the day, up 1.19% from the previous closing price of $37.01. In other words, the price has increased by $1.19 from its previous closing price. On the day, 0.62 million shares were traded. AGIO stock price reached its highest trading level at $37.55 during the session, while it also had its lowest trading level at $36.69.
Ratios:
Our analysis of AGIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 14.04 and its Current Ratio is at 14.48. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 24, 2025, initiated with a Buy rating and assigned the stock a target price of $58.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 08 ’25 when Goff Brian sold 11,085 shares for $36.67 per share. The transaction valued at 406,487 led to the insider holds 123,528 shares of the business.
Goff Brian bought 11,085 shares of AGIO for $410,810 on Aug 08 ’25. On Jul 10 ’25, another insider, Scadden David, who serves as the Director of the company, sold 1,400 shares for $40.00 each. As a result, the insider received 56,000 and left with 17,603 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 2175901184 and an Enterprise Value of 1285724800. As of this moment, Agios’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.39. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.23 while its Price-to-Book (P/B) ratio in mrq is 1.59. Its current Enterprise Value per Revenue stands at 31.455 whereas that against EBITDA is -2.818.
Stock Price History:
The Beta on a monthly basis for AGIO is 0.87, which has changed by -0.16536659 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, AGIO has reached a high of $62.58, while it has fallen to a 52-week low of $23.42. The 50-Day Moving Average of the stock is 2.59%, while the 200-Day Moving Average is calculated to be 2.68%.
Shares Statistics:
AGIO traded an average of 743.13K shares per day over the past three months and 612700 shares per day over the past ten days. A total of 58.04M shares are outstanding, with a floating share count of 54.39M. Insiders hold about 4.40% of the company’s shares, while institutions hold 105.57% stake in the company. Shares short for AGIO as of 1753920000 were 4101620 with a Short Ratio of 5.52, compared to 1751241600 on 3780761. Therefore, it implies a Short% of Shares Outstanding of 4101620 and a Short% of Float of 7.1100004.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 7.0 analysts currently analyzing and rating the stock of Agios Pharmaceuticals Inc (AGIO).The consensus estimate for the next quarter is -$1.96, with high estimates of -$1.75 and low estimates of -$2.2.
Analysts are recommending an EPS of between -$6.99 and -$7.65 for the fiscal current year, implying an average EPS of -$7.38. EPS for the following year is -$7.06, with 7.0 analysts recommending between -$5.85 and -$9.34.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $12.5M to a low estimate of $9M. As of the current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $8.96MFor the next quarter, 8 analysts are estimating revenue of $14.14M. There is a high estimate of $15.9M for the next quarter, whereas the lowest estimate is $11.8M.
A total of 8 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $47.9M, while the lowest revenue estimate was $42.8M, resulting in an average revenue estimate of $45.85M. In the same quarter a year ago, actual revenue was $36.5MBased on 8 analysts’ estimates, the company’s revenue will be $115.63M in the next fiscal year. The high estimate is $161.76M and the low estimate is $87.72M.
